Clinical Trial: A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT06916793) titled 'A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia' on April 01.

Brief Summary: This is a multi-centers, randomized, double-blind, parallel-group, Phase 3 Trial to evaluate the efficacy and safety of CKD-843 in Male patients with Androgenetic Alopecia

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: Androgenetic Alopecia

Intervention: DRUG: CKD-843 dose#1

IM injection every 3 months for 12 months

DRUG: CKD-843 dose#2

IM injection every 3 months for 12 months

DRUG: Placebo of CKD-843 dose

IM injection every 3 months for 12 months

DRUG: Dutasteride Cap...